Hypermarcas (OTCMKTS:HYPMY) Raised to “Hold” at Zacks Research

Hypermarcas (OTCMKTS:HYPMY) was upgraded by equities researchers at Zacks Research to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Hypermarcas Stock Performance

Shares of OTCMKTS:HYPMY opened at $4.69 on Wednesday. Hypermarcas has a 52 week low of $3.71 and a 52 week high of $5.50. The stock has a market capitalization of $3.30 billion, a P/E ratio of 9.77 and a beta of 0.75. The firm has a fifty day simple moving average of $4.42 and a two-hundred day simple moving average of $4.47. The company has a quick ratio of 0.84, a current ratio of 1.27 and a debt-to-equity ratio of 0.61.

Hypermarcas (OTCMKTS:HYPMY) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.10 EPS for the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. The business had revenue of $383.13 million during the quarter. On average, analysts expect that Hypermarcas will post 0.53 earnings per share for the current fiscal year.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.